An announcement from N2OFF ( (NITO) ) is now available.
On February 26, 2025, N2OFF announced a definitive agreement to acquire MitoCareX Bio Ltd., a biotech company specializing in computational drug discovery targeting hard-to-treat cancers. The acquisition involves a securities purchase and exchange agreement, with N2OFF purchasing shares from SciSparc Ltd. and exchanging additional shares with all sellers. MitoCareX will become a wholly owned subsidiary of N2OFF, with a reconstituted board. The transaction is subject to stockholder approval and includes financial commitments from N2OFF to support MitoCareX’s operations for two years. This acquisition positions N2OFF to expand into the cancer therapeutics market, potentially benefiting from MitoCareX’s innovative drug discovery approach.
More about N2OFF
N2OFF, Inc. is a clean tech company focused on sustainable solutions for solar energy, energy battery storage, and agri-tech innovation. The company aims to reduce greenhouse gas emissions and promote environmentally friendly agricultural practices. It has recently entered the solar PV market and provides funding for renewable energy projects.
YTD Price Performance: -46.36%
Average Trading Volume: 21,964,134
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $7.9M
Find detailed analytics on NITO stock on TipRanks’ Stock Analysis page.